Friday, May 5, 2023
8:00 - 9:00  
9:00 - 9:15

Introduction to the Programme

Harley Eisman, MD, Co-Founder, Hereditary Breast and Ovarian Cancer Foundation, Montréal, QC, Canada

William Foulkes, MBBS, PhD, Director, Program in Cancer Genetics, McGill University, Montréal, QC, Canada

Population-based testing for HBOC-related genes – Pros and cons
9:15 - 10:45

CHAIR: Ranjit Manchanda, MD, MRCOG, PhD, Wolfson Institute of Population Health, Queen Mary University of London, London, UK

9:15 - 9:35

Testing the limits of population-based testing

Mark Robson, MD, Memorial Sloan Kettering Cancer Center, New York, NY, USA

9:35 - 9:55

Population testing for HBOC genes: time for action

Funmi Olopade, MD, FACP, OON, Center for Clinical Cancer Genetics, University of Chicago Medicine, Chicago, IL, USA

9:55 - 10:05

Hereditary cancer testing In an unselected 'Healthy' Canadian population: Is it time to consider population screening?

Jessica Gu, MSc, MS, Medcan, Toronto, ON, Canada

10:05 - 10:15

Implementation and outcomes of a program to increase hereditary cancer testing ordered by genetics and non-genetics providers in over 12,500 patients

Monica Alvarado, MS, LCGC, Kaiser Permanente Southern California, Pasadena, CA, United States

10:17 - 10:20

Genetic contribution of BRCA1 in hereditary breast and ovarian cancer in Senegalese women

Rokhaya Ndiaye, PhD, University Cheikh Anta Diop, Dakar, Senegal

10:20 - 10:23

Early insights from the DNA screen study, an Australian pilot study of population genomic screening

Tu Nguyen-Dumont, PhD, Monash University, Clayton, VIC, Australia

10:25 - 10:45

Question and discussion period (all speakers)

10:45 - 11:15  
Special Interest Groups (SIGs)
11:15 - 12:45

Moderated 90-minute interactive discussions with the aim of fostering bilateral knowledge transfer. Choice of one of the following 2 SIGs.

SIG 7:

Alternative Models of Service Delivery

In this session, the presenters will explore alternative models of cancer genetics service delivery that have arisen in response to expanding indications for genetic testing, increasing demand for hereditary cancer services and the need to dramatically improve cascade genetic testing rates. Attendees will be encouraged to send in questions relating to these topics in advance for discussion at the SIG.

  • Intan Schrader, MBBS, PhD, BC Cancer, Vancouver, BC, Canada (session lead)

  • Kelly Metcalfe, RN, PhD, Women's College Research Institute, University of Toronto, On, Canada

  • Nicoline Hoogerbrugge, MD, PhD, Radboud University Medical Center, Nijmegen, The Netherlands

SIG 8:

The lower risk and rarer breast and/or ovarian cancer genes – What do we know and what should we do with what we know? (e.g. CHEK2, ATM, BRIP1, BARD1, NTHL1)

Presenters will provide a brief update about risk estimates in lower risk breast and ovarian cancer genes, and management based on available practice guidelines. They will review risks of contralateral breast cancer (where available), discuss causation versus coincidence when these genes are identified, gaps in literature, and future directions. Attendees will be encouraged to send in specific cases in advance for discussion at the SIG.

  • Tuya Pal, MD, Vanderbilt – Ingram Cancer Center, Nashville, TN, USA (session lead)

  • Raymond Kim, MD, PhD, Princess Margaret Cancer Centre, Toronto, ON, Canada

  • Helen Hanson, MBBS, MD(Res), St George's Hospital, London, UK

  • Marc Tischkowitz, MD, PhD, University of Cambridge, Cambridge, UK

The Marla Miller Memorial Lecture
13:00 - 14:15

Introductory Remarks

William Foulkes, MBBS, PhD, Director, Program in Cancer Genetics, McGill University, Montréal, QC, Canada

Optimizing Treatment of Breast Cancer in BRCA1 Carriers

Steven Narod, MD, PhD, Senior Scientist, Women’s College Hospital, Toronto, ON, Canada

Presentation by the Miller Family

Closing Remarks

Harley Eisman, MD, Co-Founder, Hereditary Breast and Ovarian Cancer Foundation, Montréal, QC, Canada

Marla Miller-Gross
Marla Miller-Gross passed away less than two years after being diagnosed with "routine" breast cancer, months shy of her fortieth birthday. Marla's courage in opting for genetic testing has touched lives far far beyond those that she befriended while living.

Out of Marla's tragedy, HBOC was born and the drive to improve the outcome of women and families with hereditary breast and ovarian cancer.